Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 71.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,241 shares of the biopharmaceutical company's stock after selling 36,080 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in Gilead Sciences were worth $1,452,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock worth $594,370,000 after buying an additional 5,653,075 shares during the period. Raymond James Financial Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at $207,340,000. Finally, Point72 Asset Management L.P. raised its position in Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock worth $193,274,000 after acquiring an additional 1,793,145 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Remove Ads

Gilead Sciences Stock Down 1.6 %

Shares of Gilead Sciences stock traded down $1.91 during trading on Tuesday, hitting $115.30. 6,924,730 shares of the stock were exchanged, compared to its average volume of 8,147,783. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $143.59 billion, a price-to-earnings ratio of 311.66, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The firm's 50-day moving average price is $100.12 and its 200 day moving average price is $91.91.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.74%. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Citigroup started coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective on the stock. Finally, Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold 293,356 shares of company stock valued at $29,166,240 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.